DK1117435T3 - Muteret cholera-holotoxin som adjuvans - Google Patents
Muteret cholera-holotoxin som adjuvansInfo
- Publication number
- DK1117435T3 DK1117435T3 DK99951639T DK99951639T DK1117435T3 DK 1117435 T3 DK1117435 T3 DK 1117435T3 DK 99951639 T DK99951639 T DK 99951639T DK 99951639 T DK99951639 T DK 99951639T DK 1117435 T3 DK1117435 T3 DK 1117435T3
- Authority
- DK
- Denmark
- Prior art keywords
- adjuvant
- amino acid
- holotoxin
- cholera holotoxin
- mutant cholera
- Prior art date
Links
- 206010008631 Cholera Diseases 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 229930186900 holotoxin Natural products 0.000 abstract 3
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 241000233866 Fungi Species 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10243098P | 1998-09-30 | 1998-09-30 | |
PCT/US1999/022520 WO2000018434A1 (fr) | 1998-09-30 | 1999-09-30 | Holotoxine mutante du cholera utilisee comme adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1117435T3 true DK1117435T3 (da) | 2008-03-17 |
Family
ID=22289805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99951639T DK1117435T3 (da) | 1998-09-30 | 1999-09-30 | Muteret cholera-holotoxin som adjuvans |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1117435B1 (fr) |
JP (1) | JP4673974B2 (fr) |
KR (1) | KR100659803B1 (fr) |
CN (1) | CN1197618C (fr) |
AT (1) | ATE378066T1 (fr) |
AU (1) | AU770333B2 (fr) |
BR (1) | BR9914160A (fr) |
CA (1) | CA2344740C (fr) |
CY (1) | CY1107276T1 (fr) |
DE (1) | DE69937571T2 (fr) |
DK (1) | DK1117435T3 (fr) |
ES (1) | ES2293735T3 (fr) |
IL (2) | IL142231A0 (fr) |
MX (1) | MXPA01003228A (fr) |
PT (1) | PT1117435E (fr) |
WO (1) | WO2000018434A1 (fr) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
DK0725653T3 (da) | 1993-10-05 | 2004-10-11 | Celltech Pharmaceuticals Ltd | Vaccinepræparater |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
AU2001268662A1 (en) | 2000-06-23 | 2002-01-08 | Wyeth Holdings Corporation | Assembly of wild-type and chimeric influenza virus-like particles (VLPs) |
EP1355918B9 (fr) | 2000-12-28 | 2012-01-25 | Wyeth LLC | Proteine protectrice recombinee issue de $i(streptococcus pneumoniae) |
EP2258842A1 (fr) | 2001-04-16 | 2010-12-08 | Wyeth Holdings Corporation | Cadres de lecture ouverts de streptococcus pneumoniae codant pour des antigènes polypeptidiques, et leurs utilisations |
EP1404368B1 (fr) | 2001-06-07 | 2009-12-09 | Wyeth Holdings Corporation | Formes mutantes de l'holotoxine du cholera en tant qu'adjuvant |
KR20080078717A (ko) | 2001-06-07 | 2008-08-27 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
MXPA04000653A (es) | 2001-07-27 | 2004-11-22 | Chiron Srl | Adhesinas de meningococcus nada, app y orf 40. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
MXPA04008890A (es) | 2002-03-15 | 2005-10-18 | Wyeth Corp | Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida. |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
EP1603950A2 (fr) * | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene |
MXPA05011110A (es) * | 2003-04-16 | 2006-01-24 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. |
WO2005020902A2 (fr) | 2003-08-21 | 2005-03-10 | Cytokine Pharmasciences, Inc. | Compositions et methodes therapeutiques et diagnostiques du syndrome du colon irritable |
HUE026000T2 (en) | 2003-12-17 | 2016-04-28 | Wyeth Llc | Immunogenic peptide-bearing conjugates and methods for their preparation |
SG182189A1 (en) | 2003-12-17 | 2012-07-30 | Elan Pharma Int Ltd | A(beta) immunogenic peptide carrier conjugates and methods of producing same |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
KR20070029708A (ko) | 2004-05-21 | 2007-03-14 | 와이어쓰 | 스타필로코커스 아우레우스의 변형 피브로넥틴-결합 단백질 |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
WO2006041819A1 (fr) | 2004-10-06 | 2006-04-20 | Medimmune Vaccines, Inc. | Compositions vaccinales antigrippales stables a des temperatures de refrigerateur |
EP1802335A2 (fr) | 2004-10-21 | 2007-07-04 | Wyeth a Corporation of the State of Delaware | Compositions immunogenes a base de polypeptides antigenes de staphylococcus epidermidis |
EP2425855A1 (fr) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Composition conjuguée polysaccharide-protéine pneumococcique polyvalente |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
PT2495307T (pt) | 2006-07-13 | 2018-05-10 | Wyeth Llc | Produção do fator ix de coagulação com padrão melhorado de glicosilação |
EP2395077A1 (fr) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Substances inhibant la glycolyse dans une culture de cellules |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
AU2008223133A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
EP3301116A1 (fr) | 2008-08-25 | 2018-04-04 | Dana Farber Cancer Institute, Inc. | Epitope conservé d'hémagglutinine, anticorps contre l'épitope et procédés d'utilisation |
CN102203122A (zh) | 2008-11-05 | 2011-09-28 | 惠氏有限责任公司 | 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物 |
US8329188B2 (en) | 2008-11-12 | 2012-12-11 | Theraclone Sciences, Inc. | Human M2e peptide immunogens |
EP2571980A4 (fr) | 2010-05-19 | 2014-02-26 | Bioproperties Pty Ltd | Procédés relatifs à un mycoplasme atténué |
PL2575870T3 (pl) | 2010-06-04 | 2017-05-31 | Wyeth Llc | Preparaty szczepionek |
SI3246044T2 (sl) | 2010-08-23 | 2024-06-28 | Wyeth Llc | Stabilne formulacije antigenov neisseria meningitidis RLP2086 |
ES2585328T5 (es) | 2010-09-10 | 2022-12-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
RU2665841C2 (ru) | 2012-03-09 | 2018-09-04 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их применения |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
MX2015000789A (es) | 2012-07-19 | 2015-05-07 | Zoetis Llc | Composiciones de virus de la gripe bovina. |
AU2013295770A1 (en) | 2012-07-27 | 2015-01-29 | Zoetis Services Llc | Tick toxin compositions |
WO2014027302A1 (fr) | 2012-08-16 | 2014-02-20 | Pfizer Inc. | Procédés de glycoconjugaison et compositions |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
JP2016512841A (ja) | 2013-03-15 | 2016-05-09 | ゾエティス・サービシーズ・エルエルシー | 多価ワクチンによるb.トレハロシ感染に対するウシの干渉効果 |
EP3041502A2 (fr) | 2013-09-08 | 2016-07-13 | Pfizer Inc. | Compositions utilisables contre neisseria meningitidis et procédés associés |
EP3583947B1 (fr) | 2014-01-21 | 2023-10-11 | Pfizer Inc. | Polysaccharides capsulaires de streptococcus pneumoniae et leurs conjugués |
ES2883343T3 (es) | 2014-01-21 | 2021-12-07 | Pfizer | Polisacáridos capsulares de Streptococcus pneumoniae y conjugados de los mismos |
US10668164B2 (en) | 2014-02-14 | 2020-06-02 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
CN108135989B (zh) | 2015-08-14 | 2022-08-09 | 硕腾服务有限责任公司 | 牛支原体组合物 |
WO2017123201A1 (fr) | 2016-01-11 | 2017-07-20 | Zoetis Services Llc | Nouvelles compositions vaccinales à protection croisée pour le virus de la diarrhée épidémique porcine |
US11191822B2 (en) | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (fr) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Composition de conjugués de polysaccharide-protéine pneumococcique |
IL267733B2 (en) | 2017-01-31 | 2023-10-01 | Pfizer | NEISSERIA MENINGITIDIS preparations and methods therefor |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
BR112019027387A8 (pt) | 2017-06-23 | 2022-12-06 | Univ Maryland | Composições imunogênicas |
EP3574915A1 (fr) | 2018-05-29 | 2019-12-04 | Neovacs | Produit immunogène comprenant de l'il-4 et/ou de l'il-13 pour traiter des troubles associés à une expression ou une activité aberrantes de l'il-4 et/ou de l'il-13 |
MX2022001241A (es) | 2019-07-31 | 2022-04-20 | Sanofi Pasteur Inc | Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos. |
US20230233652A1 (en) | 2020-04-16 | 2023-07-27 | Par'immune Sas | 28 kda gst proteins from schistosoma for the treatment of vasculitis |
EP3900739A1 (fr) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée |
CA3192500A1 (fr) | 2020-09-17 | 2022-03-24 | Laurent REBER | Produit immunogene comprenant un fragment d'ige pour le traitement de troubles inflammatoires medies par l'ige |
WO2024069420A2 (fr) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Compositions immunogènes comprenant un trimère de protéine f rsv |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
AU6505796A (en) * | 1995-07-26 | 1997-02-26 | Maxim Pharmaceuticals | Mucosal delivery of polynucleotides |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
WO1998045324A1 (fr) * | 1997-04-04 | 1998-10-15 | The Uab Research Foundation | Utilisation des mutants de la toxine du cholera comme adjuvants muqueux |
-
1999
- 1999-09-30 MX MXPA01003228A patent/MXPA01003228A/es not_active IP Right Cessation
- 1999-09-30 DE DE69937571T patent/DE69937571T2/de not_active Expired - Lifetime
- 1999-09-30 AU AU64039/99A patent/AU770333B2/en not_active Ceased
- 1999-09-30 CN CNB998115576A patent/CN1197618C/zh not_active Expired - Fee Related
- 1999-09-30 ES ES99951639T patent/ES2293735T3/es not_active Expired - Lifetime
- 1999-09-30 WO PCT/US1999/022520 patent/WO2000018434A1/fr active IP Right Grant
- 1999-09-30 IL IL14223199A patent/IL142231A0/xx unknown
- 1999-09-30 EP EP99951639A patent/EP1117435B1/fr not_active Expired - Lifetime
- 1999-09-30 PT PT99951639T patent/PT1117435E/pt unknown
- 1999-09-30 AT AT99951639T patent/ATE378066T1/de not_active IP Right Cessation
- 1999-09-30 BR BR9914160-4A patent/BR9914160A/pt not_active Application Discontinuation
- 1999-09-30 JP JP2000571951A patent/JP4673974B2/ja not_active Expired - Fee Related
- 1999-09-30 DK DK99951639T patent/DK1117435T3/da active
- 1999-09-30 CA CA2344740A patent/CA2344740C/fr not_active Expired - Fee Related
- 1999-09-30 KR KR1020017003968A patent/KR100659803B1/ko not_active IP Right Cessation
-
2001
- 2001-03-25 IL IL142231A patent/IL142231A/en not_active IP Right Cessation
-
2008
- 2008-02-01 CY CY20081100125T patent/CY1107276T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU770333B2 (en) | 2004-02-19 |
EP1117435B1 (fr) | 2007-11-14 |
ES2293735T3 (es) | 2008-03-16 |
IL142231A (en) | 2010-05-31 |
IL142231A0 (en) | 2002-03-10 |
CY1107276T1 (el) | 2012-11-21 |
EP1117435A1 (fr) | 2001-07-25 |
AU6403999A (en) | 2000-04-17 |
JP2002525093A (ja) | 2002-08-13 |
JP4673974B2 (ja) | 2011-04-20 |
WO2000018434A1 (fr) | 2000-04-06 |
KR100659803B1 (ko) | 2006-12-19 |
ATE378066T1 (de) | 2007-11-15 |
DE69937571T2 (de) | 2008-09-04 |
KR20010085859A (ko) | 2001-09-07 |
DE69937571D1 (de) | 2007-12-27 |
PT1117435E (pt) | 2008-02-21 |
CN1197618C (zh) | 2005-04-20 |
CN1320043A (zh) | 2001-10-31 |
CA2344740A1 (fr) | 2000-04-06 |
CA2344740C (fr) | 2011-11-22 |
MXPA01003228A (es) | 2003-06-24 |
BR9914160A (pt) | 2001-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1117435T3 (da) | Muteret cholera-holotoxin som adjuvans | |
DE60234695D1 (de) | Mutantenformen von cholera holotoxin als adjuvans | |
MXPA03011135A (es) | Formas mutantes de holotoxina de colera como adyuvante. | |
BR9906927A (pt) | Proteìnas de neisseria meningitidis | |
ATE460484T1 (de) | 85 kda antigen von neisseria | |
DE60020677D1 (de) | Mikroemulsionen mit adsorbierten makromolekülen und mikropartikeln | |
DK1800692T3 (da) | Immunologiske sammensætninger og vacciner indeholdende N-formyl-methionyl-peptid som adjuvans | |
WO2004083251A3 (fr) | Holotoxine du cholera mutante en tant qu'adjuvant et proteine de support d'antigene | |
NO20054701L (no) | Vaksinesammensetninger som inneholder 3-0-deacetylert monofosforyl lipid A | |
DK1113816T3 (da) | Influenzavirus-vaccinesammensætning | |
NO922772D0 (no) | Siloxankopolymerer som oppviser alkenylgrupper, og fremstilling og anvendelse av siloxankopolymerene | |
NO20015074D0 (no) | Nye sammensetninger | |
DE60226175D1 (de) | Mycobakterieller impfstoff | |
PT1575483E (pt) | Bactérias gram negativas atenuadas | |
WO2000050073A3 (fr) | Immunoadjuvant de lps de caulobacter | |
FI934331A0 (fi) | Nya proteaser | |
DK0757556T3 (da) | Borrelia Burgdorferi-bakterin | |
DK1350796T3 (da) | Attenuerede gramnegative bakterier | |
ATE431745T1 (de) | Ltb4 als adjuvans für impfstoffe | |
DK0721782T3 (da) | Influenzavaccine indeholdende pertussistoksin | |
RU2227043C2 (ru) | Антигены neisseria meningitidis и композиции |